ATLANTA, Jan. 23, 2012 (GLOBE NEWSWIRE) -- OTC Stock Review announces that it has initiated coverage of Aperture Health, Inc. (OTC:APRE). APRE recently acquired Triad Therapeutics, Inc., ("Triad") a homecare infusion therapy and nursing provider in New Jersey. As a result, Triad has become a wholly owned subsidiary of Aperture Health, Inc., and will remain as the operating company for the combined business.
Triad Therapeutics, Inc.
Triad provides specialized home healthcare services to patients requiring intravenous therapy including antibiotics, pain management, hydration, immunoglobulins, steroids, total nutritional solutions, and IV catheter insertions and maintenance. Simply put, Triad provides a complete solution to patients including the preparation and delivery of sterile compounded IV medications, supplies and equipment, along with specialized nursing care and teaching of the patient and/or caregivers on the administration of therapies as prescribed by a licensed physician.
Triad is a fully accredited home IV therapy company, achieving this "gold standard" status in 2007. Triad has built a well-respected reputation in its industry, which includes companies like Catasys, Inc., Magellan Health Services, Centene Corp., Amerigroup Corporation, Unity Management Group, and Express Scripts, Inc. Triad currently services clients in New Jersey, New York, and Connecticut. In our opinion, serving these populated areas in the northeastern United States provides APRE significant opportunity for organic growth by Triad.
The complete report is available at http://www.otcstockreview.com/APRE_Review.pdf.
Additionally, more information on Aperture Health, Inc. is available at http://www.triadtx.net.
NOTE: The purpose of this release is to introduce the reader to OTCStockReview.com and Aperture Health, Inc. OTC Stock Review is not a Registered Investment Advisor or a Broker/Dealer. Information and opinions presented in this release are solely for informative purposes and not intended, nor should they be construed as, investment advice. This document contains information obtained from public sources about Aperture Health, Inc., but does not contain all the relevant material information necessary to evaluate the company. This release is not to be considered an offer to buy, sell, hold, and/or otherwise trade in the securities of Aperture Health, Inc., as profiled. OTC Stock Review has not been compensated to perform investor relations services for Aperture Health, Inc., but expects to be compensated in the future. Officers, directors, and employees of OTC Stock Review, may hold a long or short equity position of a profiled company and may trade in these securities for their own accounts. Carefully review profiled companies with your investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Readers are encouraged to obtain copies of the profiled Company's periodic reports filed with United States Securities and Exchange Commission, which are generally available at http://www.sec.gov. You can view our complete disclaimer at http://www.otcstockreview.com/disclaimer.htm